XILIO THERAPEUTICS, INC.

$2.92 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About XILIO THERAPEUTICS, INC.

Xilio Therapeutics, Inc. is a biotechnology company. The Company is focused on harnessing the immune system to achieve clinical responses for cancer patients. It offers a geographically precise solutions (GPS) platform to engineer molecules, including cytokines and other biologics, that are designed to enhance therapeutic index. Using its GPS platform, the Company is engaged in developing a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. Its product candidates include XTX101, XTX202, XTX301, and XTX401. XTX101 is a clinical-stage, tumor-selective anti-cytotoxic T-lymphocyte-associated protein (CTLA-4), monoclonal antibody (mAb), which is designed to improve upon the therapeutic index of existing anti-CTLA-4 therapies. XTX202 and XTX301 are an engineered form of interleukin 2 (IL-2) that is masked with a protein domain to prevent binding activity until the protein domain is cleaved off by tumor microenvironment (TME)-associated proteases.

Stock Analysis

last close $2.92
1-mo return -2.7%
3-mo return -58.7%
avg daily vol. 162.43T
52-week high 27.95
52-week low 2.04
market cap. $66M
forward pe -
annual div. -
roe -250%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 81.3%
baraka

Subscribe now for daily local and international financial news

Subscribe